Masayuki Amano

List of Publications by Year
in descending order

53	1,380	331538	360920
papers	citations	21 h-index	35 g-index

59	59	59	1175
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Fluorine Modifications Contribute to Potent Antiviral Activity against Highly Drug-Resistant HIV-1 and Favorable Blood-Brain Barrier Penetration Property of Novel Central Nervous System-Targeting HIV-1 Protease Inhibitors In Vitro. Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0171521.	1.4	5
2	Design, Synthesis and Xâ€Ray Structural Studies of Potent HIVâ€1 Protease Inhibitors Containing Câ€4 Substituted Tricyclic Hexahydroâ€Furofuran Derivatives as P2 Ligands. ChemMedChem, 2022, 17, .	1.6	2
3	Third-Dose BNT162b2 Vaccination Elicits Markedly High-Level SARS-CoV-2â€“Neutralizing Antibodies in Vaccinees Who Responded Poorly to a Second Dose in Japan. Journal of Infectious Diseases, 2022, 226, 2038-2039.	1.9	7
4	Human retroviral antisense mRNAs are retained in the nuclei of infected cells for viral persistence. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	23
5	A Small Molecule, ACAi-028, with Anti-HIV-1 Activity Targets a Novel Hydrophobic Pocket on HIV-1 Capsid. Antimicrobial Agents and Chemotherapy, 2021, 65, e0103921.	1.4	11
6	Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals. Scientific Reports, 2021, 11, 22848.	1.6	57
7	Synthesis and evaluation of the anti-hepatitis B virus activity of 4â€²-Azido-thymidine analogs and 4â€²-Azido-2â€²-deoxy-5-methylcytidine analogs: structural insights for the development of a novel anti-HBV agent. Nucleosides, Nucleotides and Nucleic Acids, 2020, 39, 518-529.	0.4	2
8	A Conformational Escape Reaction of HIV-1 against an Allosteric Integrase Inhibitor. Journal of Virology, 2020, 94, .	1.5	7
9	Structure-Based Design of Highly Potent HIV-1 Protease Inhibitors Containing New Tricyclic Ring P2-Ligands: Design, Synthesis, Biological, and X-ray Structural Studies. Journal of Medicinal Chemistry, 2020, 63, 4867-4879.	2.9	19
10	Novel p97/<scp>VCP</scp> inhibitor induces endoplasmic reticulum stress and apoptosis in both bortezomibâ€sensitive and â€resistant multiple myeloma cells. Cancer Science, 2019, 110, 3275-3287.	1.7	23
11	Amino-acid inserts of HIV-1 capsid (CA) induce CA degradation and abrogate viral infectivity: Insights for the dynamics and mechanisms of HIV-1 CA decomposition. Scientific Reports, 2019, 9, 9806.	1.6	5
12	Novel Central Nervous System (CNS)-Targeting Protease Inhibitors for Drug-Resistant HIV Infection and HIV-Associated CNS Complications. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	9
13	Novel Protease Inhibitors Containing C-5-Modified bis-Tetrahydrofuranylurethane and Aminobenzothiazole as P2 and P2â€² Ligands That Exert Potent Antiviral Activity against Highly Multidrug-Resistant HIV-1 with a High Genetic Barrier against the Emergence of Drug Resistance. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	11
14	Synthesis of 4â€²â€Substituted Purine 2â€²â€Deoxynucleosides and Their Activity against Human Immunodeficiency Virus Type 1 and Hepatitis B Virus. ChemistrySelect, 2018, 3, 3313-3317.	0.7	6
15	Synthesis, Anti-HBV, and Anti-HIV Activities of 3â€²-Halogenated Bis(hydroxymethyl)-cyclopentenyladenines. ACS Medicinal Chemistry Letters, 2018, 9, 1211-1216.	1.3	7
16	Design and Synthesis of Highly Potent HIV-1 Protease Inhibitors Containing Tricyclic Fused Ring Systems as Novel P2 Ligands: Structureâ€“Activity Studies, Biological and X-ray Structural Analysis. Journal of Medicinal Chemistry, 2018, 61, 4561-4577.	2.9	31
17	Design of novel HIV-1 protease inhibitors incorporating isophthalamide-derived P2-P3 ligands: Synthesis, biological evaluation and X-ray structural studies of inhibitor-HIV-1 protease complex. Bioorganic and Medicinal Chemistry, 2017, 25, 5114-5127.	1.4	16
18	A novel entecavir analogue constructing with a spiro[2.4]heptane core structure in the aglycon moiety: Its synthesis and evaluation for anti-hepatitis B virus activity. Nucleosides, Nucleotides and Nucleic Acids, 2017, 36, 463-473.	0.4	6

#	Article	IF	Citations
19	GRL-09510, a Unique P2-Crown-Tetrahydrofuranylurethane -Containing HIV-1 Protease Inhibitor, Maintains Its Favorable Antiviral Activity against Highly-Drug-Resistant HIV-1 Variants in vitro. Scientific Reports, 2017, 7, 12235.	1.6	16
20	Design, synthesis, X-ray studies, and biological evaluation of novel macrocyclic HIV-1 protease inhibitors involving the P1â€²-P2â€² ligands. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 4925-4931.	1.0	7
21	Design, Synthesis, Biological Evaluation, and Xâ€ray Studies of HIVâ€1 Protease Inhibitors with Modified P2â€² Ligands of Darunavir. ChemMedChem, 2017, 12, 1942-1952.	1.6	8
22	A Modified P1 Moiety Enhances In Vitro Antiviral Activity against Various Multidrug-Resistant HIV-1 Variants and In Vitro Central Nervous System Penetration Properties of a Novel Nonpeptidic Protease Inhibitor, GRL-10413. Antimicrobial Agents and Chemotherapy, 2016, 60, 7046-7059.	1.4	14
23	Immunomodulatory drugs act as inhibitors of DNA methyltransferases and induce PU.1 up-regulation in myeloma cells. Biochemical and Biophysical Research Communications, 2016, 469, 236-242.	1.0	10
24	Diastereoselective Synthesis of 6â€³-(Z)- and 6â€³-(E)-Fluoro Analogues of Anti-hepatitis B Virus Agent Entecavir and Its Evaluation of the Activity and Toxicity Profile of the Diastereomers. Journal of Organic Chemistry, 2016, 81, 2827-2836.	1.7	12
25	4â€²â€modified nucleoside analogs: Potent inhibitors active against entecavirâ€resistant hepatitis B virus. Hepatology, 2015, 62, 1024-1036.	3.6	43
26	A Novel Tricyclic Ligand-Containing Nonpeptidic HIV-1 Protease Inhibitor, GRL-0739, Effectively Inhibits the Replication of Multidrug-Resistant HIV-1 Variants and Has a Desirable Central Nervous System Penetration Property In Vitro. Antimicrobial Agents and Chemotherapy, 2015, 59, 2625-2635.	1.4	10
27	Structure-based design, synthesis, X-ray studies, and biological evaluation of novel HIV-1 protease inhibitors containing isophthalamide-derived P2-ligands. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 4903-4909.	1.0	26
28	Structure-Based Design of Potent HIV-1 Protease Inhibitors with Modified P1-Biphenyl Ligands: Synthesis, Biological Evaluation, and Enzymeâ€“Inhibitor X-ray Structural Studies. Journal of Medicinal Chemistry, 2015, 58, 5334-5343.	2.9	21
29	Design, Synthesis, and Evaluation of Anti-HBV Activity of Hybrid Molecules of Entecavir and Adefovir: Exomethylene Acycloguanine Nucleosides and Their Monophosphate Derivatives. Nucleosides, Nucleotides and Nucleic Acids, 2015, 34, 590-602.	0.4	4
30	Design, synthesis, biological evaluation and X-ray structural studies of HIV-1 protease inhibitors containing substituted fused-tetrahydropyranyl tetrahydrofuran as P2-ligands. Organic and Biomolecular Chemistry, 2015, 13, 11607-11621.	1.5	10
31	Design of gemâ€Difluoroâ€bisâ€Tetrahydrofuran as P2 Ligand for HIVâ€1â€…Protease Inhibitors to Improve Brain Penetration: Synthesis, Xâ€ray Studies, and Biological Evaluation. ChemMedChem, 2015, 10, 107-115.	1.6	20
32	Design and synthesis of potent macrocyclic HIV-1 protease inhibitors involving P1â€“P2 ligands. Organic and Biomolecular Chemistry, 2014, 12, 6842-6854.	1.5	20
33	Highly Potent HIV-1 Protease Inhibitors with Novel Tricyclic P2 Ligands: Design, Synthesis, and Proteinâ€“Ligand X-ray Studies. Journal of Medicinal Chemistry, 2013, 56, 6792-6802.	2.9	42
34	Comparative analysis of ER stress response into HIV protease inhibitors: Lopinavir but not darunavir induces potent ER stress response via ROS/JNK pathway. Free Radical Biology and Medicine, 2013, 65, 778-788.	1.3	32
35	GRL-04810 and GRL-05010, Difluoride-Containing Nonpeptidic HIV-1 Protease Inhibitors (PIs) That Inhibit the Replication of Multi-PI-Resistant HIV-1 In Vitro and Possess Favorable Lipophilicity That May Allow Blood-Brain Barrier Penetration. Antimicrobial Agents and Chemotherapy, 2013, 57, 6110-6121.	1.4	21
36	GRL-0519, a Novel Oxatricyclic Ligand-Containing Nonpeptidic HIV-1 Protease Inhibitor (PI), Potently Suppresses Replication of a Wide Spectrum of Multi-PI-Resistant HIV-1 Variants In Vitro. Antimicrobial Agents and Chemotherapy, 2013, 57, 2036-2046.	1.4	24

#	Article	IF	Citations
37	Loss of the Protease Dimerization Inhibition Activity of Tipranavir (TPV) and Its Association with the Acquisition of Resistance to TPV by HIV-1. Journal of Virology, 2012, 86, 13384-13396.	1.5	26
38	Substituent effects on P2-cyclopentyltetrahydrofuranyl urethanes: Design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 2308-2311.	1.0	17
39	Design and Synthesis of Potent HIV-1 Protease Inhibitors Incorporating Hexahydrofuropyranol-Derived High Affinity P₂ Ligands: Structureâ˜Activity Studies and Biological Evaluation. Journal of Medicinal Chemistry, 2011, 54, 622-634.	2.9	69
40	Design of HIV-1 Protease Inhibitors with C3-Substituted Hexahydrocyclopentafuranyl Urethanes as P2-Ligands: Synthesis, Biological Evaluation, and Proteinâ€“Ligand X-ray Crystal Structure. Journal of Medicinal Chemistry, 2011, 54, 5890-5901.	2.9	31
41	Design, Synthesis, and X-ray Structure of Substituted Bis-tetrahydrofuran (Bis-THF)-Derived Potent HIV-1 Protease Inhibitors. ACS Medicinal Chemistry Letters, 2011, 2, 298-302.	1.3	26
42	Novel HIV-1 Protease Inhibitors (PIs) Containing a Bicyclic P2 Functional Moiety, Tetrahydropyrano-Tetrahydrofuran, That Are Potent against Multi-PI-Resistant HIV-1 Variants. Antimicrobial Agents and Chemotherapy, 2011, 55, 1717-1727.	1.4	25
43	Loss of Protease Dimerization Inhibition Activity of Darunavir Is Associated with the Acquisition of Resistance to Darunavir by HIV-1. Journal of Virology, 2011, 85, 10079-10089.	1.5	40
44	Probing Multidrugâ€Resistance and Proteinâ€“Ligand Interactions with Oxatricyclic Designed Ligands in HIVâ€1 Protease Inhibitors. ChemMedChem, 2010, 5, 1850-1854.	1.6	47
45	Synthesis and biological evaluation of novel allophenylnorstatine-based HIV-1 protease inhibitors incorporating high affinity P2-ligands. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 1241-1246.	1.0	14
46	Novel Protease Inhibitors (PIs) Containing Macrocyclic Components and 3(R),3a(S),6a() Tj ETQq0 0 0 rgBT /Overlock 10 Variants In Vitro. Antimicrobial Agents and Chemotherapy, 2010, 54, 3460-3470.	1.4	21
47	In Vitro Selection of Highly Darunavir-Resistant and Replication-Competent HIV-1 Variants by Using a Mixture of Clinical HIV-1 Isolates Resistant to Multiple Conventional Protease Inhibitors. Journal of Virology, 2010, 84, 11961-11969.	1.5	85
48	GRL-02031, a Novel Nonpeptidic Protease Inhibitor (PI) Containing a Stereochemically Defined Fused Cyclopentanyltetrahydrofuran Potent against Multi-PI-Resistant Human Immunodeficiency Virus Type 1 In Vitro. Antimicrobial Agents and Chemotherapy, 2009, 53, 997-1006.	1.4	38
49	Design, Synthesis, Proteinâ˜Ligand X-ray Structure, and Biological Evaluation of a Series of Novel Macrocyclic Human Immunodeficiency Virus-1 Protease Inhibitors to Combat Drug Resistance. Journal of Medicinal Chemistry, 2009, 52, 7689-7705.	2.9	40
50	Activity against Human Immunodeficiency Virus Type 1, Intracellular Metabolism, and Effects on Human DNA Polymerases of 4â€²-Ethynyl-2-Fluoro-2â€²-Deoxyadenosine. Antimicrobial Agents and Chemotherapy, 2007, 51, 2701-2708.	1.4	96
51	A Novel Bis-Tetrahydrofuranylurethane-Containing Nonpeptidic Protease Inhibitor (PI), GRL-98065, Is Potent against Multiple-PI-Resistant Human Immunodeficiency Virus In Vitro. Antimicrobial Agents and Chemotherapy, 2007, 51, 2143-2155.	1.4	66
52	Potent Inhibition of HIV-1 Replication by Novel Non-peptidyl Small Molecule Inhibitors of Protease Dimerization. Journal of Biological Chemistry, 2007, 282, 28709-28720.	1.6	137
53	Correlates of Neutralizing/SARS-CoV-2-S1-Binding Antibody Response With Adverse Effects and Immune Kinetics in BNT162b2-Vaccinated Individuals. SSRN Electronic Journal, 0, , .	0.4	0